Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perilla frutescens leaf ethanol extract is a **botanical small-molecule mixture** derived from the leaves of *Perilla frutescens* using ethanol extraction, typically standardized as a nutraceutical or research extract rather than a single defined pharmaceutical active ingredient. Reported constituents include rosmarinic acid, luteolin, perillaldehyde, caffeic acid, and other phenolic compounds. Across preclinical studies, the extract has shown multimodal bioactivity including inhibition of Src-mediated epithelial-mesenchymal transition and cancer cell migration, suppression of inflammatory signaling pathways such as NF-kB with downstream reduction of cytokines including IL-6 and TNF-a, and inhibition of enzymes implicated in cognitive impairment and Alzheimer disease such as acetylcholinesterase and beta-secretase 1. A randomized clinical study has evaluated an oral standardized 60 percent ethanol extract at 500 mg daily for cognitive impairment. The asset appears to be a non-branded botanical development or nutraceutical ingredient associated with academic research and Korean standardization efforts including S&D rather than a marketed prescription drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perilla frutescens leaf ethanol extract.